Life Sciences Practice
Sophisticated guidance for pharmaceutical, biotechnology and healthcare companies navigating regulatory, transactional and enforcement challenges.
Pharmaceutical, biotechnology and healthcare companies face a complex array of issues and require interdisciplinary legal teams that serve as true partners to their business. Our lawyers have a comprehensive understanding of our clients’ challenges, opportunities and goals and provide sophisticated and precise guidance across a complete spectrum of legal services.
Mergers and acquisitions, joint ventures, corporate transactions and licensing:
- Pharmaceutical companies entering or expanding their presence in the US, Europe, Latin America and the Asia-Pacific Basin
- Issues involving licensed pharmaceutical products, biologics and intellectual property
- Joint ventures and strategic alliances, specifically including licensing, product development, research and marketing collaborations
- Transactions involving international performance and regulatory clearances
- Creation of novel product sourcing and distribution agreements
- Negotiating and implementing agreements with contracts research organizations
Antitrust:
- Private antitrust litigation
- Criminal grand jury inquiries
- Civil governmental inquiries
- All phases of Hart-Scott Rodino
- Post-closing antitrust reviews of collaborations between competitors
- Antitrust issues attendant to product development, marketing and compliance
- Development and implementation of corporate compliance programs
- Advice regarding EU competition rules in both our domestic and Paris offices
- Competition law and enforcement in the Pacific Basin, South America, and Africa
Litigation, arbitration and dispute resolution:
- Massive product liability litigation
- Insurance coverage disputes
- General civil litigation
- Corporate reorganization and bankruptcy cases
- Alternative dispute resolution
- Pharmaceutical licensing agreements
- Patent infringement and validity lawsuits for medical and dental device companies
- False advertising claims under the Lanham Act
Food and drug law:
- Representation of multinational research-based pharmaceutical companies
- Representation of foreign and domestic medical device and cosmetics manufacturers
- US Food and Drug Administration regulatory matters
US employment law:
- Development and review of compliance programs
- Defense in discrimination, wrongful termination and breach of contract cases
- Employment agreements
- Negotiation of collective bargaining agreements with local unions
Government contracts law:
- Bid protests
- Post-award audits
- Enforcement actions
- Practice before the executive agencies, the General Services Administration, the boards of contract appeals and federal courts
- Federal Supply Schedule contracting under the Veterans Healthcare Act of 1992
Latest Updates
Commerce’s Section 232 Pharmaceutical Investigation: Opportunities for Companies Able to Comment by the May 7, 2025 Deadline
April 17, 2025 – On April 1, Secretary of Commerce Howard Lutnick initiated an investigation “to determine the effects on the national security” of the United States “of imports of pharmaceuticals and pharmaceutical ingredients, and their derivative products.” This includes “both finished generic and non-generic...
Litigation after the Demise of Chevron Deference
July 15, 2024 – As widely anticipated, the Supreme Court last month overruled Chevron U.S.A. v. Natural Resources Defense Council, Inc.,1 which directed federal courts to defer to an administrative agency’s “reasonable” interpretation of ambiguous terms in a Congressional statute authorizing the agency to act....
Chair of HHR’s Litigation Department Dan Weiner Featured in The American Lawyer’s Litigation Leaders Q&A
Dan Weiner, chair of HHR’s Litigation Department, was featured in The American Lawyer’s “Litigation Leaders” column, which highlights litigation practice leaders of the largest and most innovative law firms in the U.S. Weiner discussed his background and upbringing, and the firm’s approach to its litigation successes and largest victories over the last year. He also talked about several upcoming high-stakes matters on the firm’s docket.
Stay Up to Date
Sign up to receive practical updates, fresh perspectives and helpful guidance delivered straight to your inbox.
Stay connected for our latest news and insights.